76 Percent Of Rheumatoid Arthritis Patients On Oral JAK1/JAK2 Inhibitor Plus DMARDS Achieve ACR20 Response At Week 12

Data from a Phase IIb study presented at EULAR 2012, the Annual Congress of the European League Against Rheumatism, show that 76% of patients with active rheumatoid arthritis (RA) receiving either 4mg or 8mg of baricitinib, an oral JAK1/JAK2 inhibitor, plus stable methotrexate (MTX) achieved ACR20* response compared with 41% of placebo-treated patients (p less than or equal to 0.001) at 12 weeks...

Source: http://www.medicalnewstoday.com/releases/246359.php

Brick By Boring Brick Celebration Lil Freak Kelly Osbourne